BioAdaptives

BioAdaptives Change in Working Capital

The Change in Working Capital of BioAdaptives (BDPT) as of Oct 25, 2026 is 121,367.00 USD. In the previous year, Change in Working Capital was 76,847.00 USD — a change of 57.93% (higher).

Change in Working Capital

121,367.00USD

YoY

57.93%

Last updated:

Change in Working Capital of BioAdaptives is 2025 121,367.00 USD. Change in Working Capital of BioAdaptives was 2024 76,847.00 USD. It decreases by 57.93% higher compared to the previous year.

The BioAdaptives Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2018
8,805.00 USD
Jan 1, 2019
14,732.00 USD
Jan 1, 2020
58,279.00 USD
Jan 1, 2021
235,202.00 USD
Jan 1, 2022
182,428.00 USD
Jan 1, 2023
20,310.00 USD
Jan 1, 2024
76,847.00 USD
Jan 1, 2025
121,367.00 USD
The BioAdaptives Change in Working Capital history
YEARChange in Working CapitalYoY
121,367.00USD+57.93%
76,847.00USD+278.37%
20,310.00USD-88.87%
182,428.00USD-22.44%
235,202.00USD+303.58%
58,279.00USD+295.59%
14,732.00USD+67.31%
8,805.00USD-61.34%
22,777.00USD-81.21%
121,218.00USD-31.57%
177,140.00USD+1,564.07%
10,645.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioAdaptives Stock analysis

What does BioAdaptives do? BioAdaptives, Inc. generates revenue through the sale of health and wellness products including dietary supplements, specialty food items, and devices that optimize bioelectromagnetic availability. The company markets PrimiCell and PrimiLive under a product agreement with Ferris Holding, Inc., targeting consumers seeking cognitive enhancement, fatigue reduction, and anti-aging solutions. PrimiTrim serves the weight control segment, while Equine Regen and Equine Regen Plus are in advanced testing for veterinary use. The firm also develops a dog product, expanding its wellness offerings across human and animal health markets. Ferris Holding, Inc. provides the intellectual property and products that BioAdaptives markets, including PrimiCell and PrimiLive, which are positioned for cognition, focus, and emotional wellness. The company's advanced-stage products Equine Regen and Equine Regen Plus cater to the veterinary segment, with PrimiTrim addressing weight management needs. BioAdaptives' product portfolio spans nutraceuticals, devices, and specialty foods designed to improve physical and emotional wellness across multiple consumer segments. BioAdaptives focuses on selling devices and nutraceuticals that target cognitive performance, fatigue reduction, and anti-aging, with PrimiCell and PrimiLive as key products under the Ferris agreement. The company's weight control solution PrimiTrim appeals to consumers seeking wellness through diet, while Equine Regen and Equine Regen Plus target animal health providers. The firm's development of a dog product further diversifies its offerings in the wellness market. BioAdaptives is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioAdaptives stock

Change in Working Capital of BioAdaptives is 121,367.00 USD in 2025.

Change in Working Capital of BioAdaptives changed from 76,847.00 USD to 121,367.00 USD, representing a 57.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital BioAdaptives since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's BioAdaptives historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioAdaptives

All Key Metrics — BioAdaptives